Lee's Pharmaceutical Holdings Limited (HKG:0950)

Hong Kong · Delayed Price · Currency is HKD

1.210

+0.075 (6.61%)

Sep 18, 2026, 3:57 PM HKT

Market Cap	712.49M -53.5%
Revenue (ttm)	1.54B +7.1%
Net Income	119.77M +22.5%
EPS	0.20 +22.4%
Shares Out	588.84M
PE Ratio	5.95
Forward PE	n/a
Dividend	0.05 (3.72%)
Ex-Dividend Date	Sep 25, 2026

Volume	799,000
Open	1.140
Previous Close	1.135
Day's Range	1.140 - 1.230
52-Week Range	0.990 - 2.650
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About HKG:0950

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to trea... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1994

Employees 1,094

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 0950

Full Company Profile

Financial Performance

In 2025, HKG:0950's revenue was 1.44 billion, an increase of 2.57% compared to the previous year's 1.40 billion. Earnings were 91.94 million, a decrease of -1.25%.

Financial Statements